[B-0]22223[B-1]
[B-2]At the national level, public health authorities may issue official recommendations for the use of booster doses, either after one dose of Janssen vaccine or after two doses of mRNA vaccines.[B-3]
[B-4]The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that [B-5]a booster dose of Janssen's COVID-19 vaccine[B-6] can be given [B-7]at least 2 months after the first dose[B-8] in persons 18 years of age and older.[B-9][B-10]The recommendation follows data showing that a booster dose of Janssen vaccine, given at least 2 months after the first dose in adults,[B-11] led to an increase in antibodies[B-12] against SARS-CoV-2. [B-13]The risk of thrombosis[B-14] in combination with thrombocytopenia (TTS) or other very rare adverse events after booster dose[B-15] is not known and is being carefully monitored.[B-16][B-17][B-18]The CHMP also concluded that a booster dose with Janssen's vaccine can be administered following two doses of mRNA vaccines approved in the EU, Comirnaty (from Pfizer/BioNTech) or Spikevax (from Moderna).[B-19][B-20]As for all medicines,[B-21] the EMA will continue to review all data[B-22] on the safety and efficacy of Janssen's vaccine.[B-23][B-24][B-25]At the national level[B-26], public health authorities may issue formal recommendations for the use of booster doses, following either one dose of Janssen's vaccine or two doses of mRNA vaccines, taking into account the local epidemiological situation, vaccine availability, emerging efficacy, and limited safety data for the booster dose.[B-27][B-28]Source: APE-MPA[B-29][B-29]
[B-30]Contents of this article including associated images are belongs to [B-31]Cyprus Times[B-32]
Views & opinions expressed are those of the author and/or [B-33]Cyprus Times[B-34][B-35]
[B-36]Source[B-37]
[B-2]At the national level, public health authorities may issue official recommendations for the use of booster doses, either after one dose of Janssen vaccine or after two doses of mRNA vaccines.[B-3]
[B-4]The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that [B-5]a booster dose of Janssen's COVID-19 vaccine[B-6] can be given [B-7]at least 2 months after the first dose[B-8] in persons 18 years of age and older.[B-9][B-10]The recommendation follows data showing that a booster dose of Janssen vaccine, given at least 2 months after the first dose in adults,[B-11] led to an increase in antibodies[B-12] against SARS-CoV-2. [B-13]The risk of thrombosis[B-14] in combination with thrombocytopenia (TTS) or other very rare adverse events after booster dose[B-15] is not known and is being carefully monitored.[B-16][B-17][B-18]The CHMP also concluded that a booster dose with Janssen's vaccine can be administered following two doses of mRNA vaccines approved in the EU, Comirnaty (from Pfizer/BioNTech) or Spikevax (from Moderna).[B-19][B-20]As for all medicines,[B-21] the EMA will continue to review all data[B-22] on the safety and efficacy of Janssen's vaccine.[B-23][B-24][B-25]At the national level[B-26], public health authorities may issue formal recommendations for the use of booster doses, following either one dose of Janssen's vaccine or two doses of mRNA vaccines, taking into account the local epidemiological situation, vaccine availability, emerging efficacy, and limited safety data for the booster dose.[B-27][B-28]Source: APE-MPA[B-29][B-29]
[B-30]Contents of this article including associated images are belongs to [B-31]Cyprus Times[B-32]
Views & opinions expressed are those of the author and/or [B-33]Cyprus Times[B-34][B-35]
[B-36]Source[B-37]
